Tactile Medical's Spending Outpaces Sales: Rapid Earnings Reaction
Tactile Systems Technology (TCMD) reported Q3 revenue growth of 7% to $91.9M, but net income declined. Lymphedema revenue rose 13%, while airway clearance revenue dropped 25%. Spending outpaced sales, causing profit to fall. Shares fell 8% in after-hours trading. Management maintained 2026 revenue outlook but slightly raised adjusted EBITDA forecast.
How this was made
The 30-second read
Why it matters
The market reaction centers on operating expense growth outpacing revenue growth, leading to lower operating income and a fourth-quarter adjusted EBITDA outlook that implies a weaker finish versus last year.
Market read
Traders should monitor whether airway clearance revenue rebounds in Q4 and whether expense growth slows to align with sales momentum.
What to watch
Gross margin improved (77% vs 76%), and management nudged up adjusted EBITDA guidance, suggesting the expense overhang could be partially offset by mix and manufacturing cost benefits if sales accelerate.
Background
Tactile launched a new AffloVest vest version in Q2, and the release attributes airway clearance revenue weakness to supplier inventory working through the transition.
Ticker impact
Tactile Systems Technology reported Q3 revenue up 7% to $91.9M but operating expenses up 13%, sending shares down about 8% after hours.
Likely near-term pressure as investors focus on whether fourth-quarter expense growth slows and whether airway clearance orders normalize after the AffloVest update.
The article ties the after-hours drop to operating income falling (to $9.6M from $11.0M) and notes the fourth-quarter adjusted EBITDA outlook implies a weaker finish.
Market effects
Highlights execution risk for medical device companies where product transitions can temporarily disrupt channel inventory and timing of orders.
No clear regional spillover beyond US small/mid-cap medical device sentiment.
Limited global relevance; story is company-specific around product cycle and expense discipline.
Counterpoint
The airway clearance dip may be largely timing-related from supplier inventory drawdown during the AffloVest version switch, so revenue could rebound once orders normalize.
Key entities
- companyTactile Systems Technology
NASDAQ-listed medical device company whose Q3 results and Q4 EBITDA outlook drove an after-hours selloff.
